Impact of the introduction of minimally invasive treatments of the thyroid (MITT) for benign thyroid nodules in an Italian hospital: a cost-minimization analysis.
.
Benign thyroid nodules
Laser ablation
MITT
Minimally invasive treatments of the thyroid
Radiofrequency ablation
Thermal ablation
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
19
02
2023
accepted:
15
05
2023
medline:
29
8
2023
pubmed:
1
6
2023
entrez:
31
5
2023
Statut:
ppublish
Résumé
Prevalence of thyroid nodules is high in the adult population, approaching 60% in women and older people. Most thyroid nodules are benign and asymptomatic. However, a not negligible part of them causes compressive symptoms and/or cosmetic concerns and need to be treated. In the last two decades, minimally-invasive treatments of the thyroid (MITT) have been proposed in routine clinical practice as a reliable cost-effective alternative to surgery in patients with symptomatic benign thyroid nodules (SBTNs). To perform a cost-minimization analysis comparing direct, indirect and intangible costs of radiofrequency (RFA) and laser thermal ablation (LTA) with traditional surgery in patients with SBTNs. Data of patients treated by MITT for SBTNs from October 1st 2019 to September 30th 2022 in a single Italian tertiary Center were analyzed. Costs were compared to those of traditional surgery reported in the 2022 Associazione Medici Endocrinologi Guidelines on the Management of SBTNs. In the study lapse, 157 MITT of SBTNs were performed in 148 patients, 114 females and 34 males (mean age: 59 yrs; median age: 57 yrs). Before MITT, the mean thyroid nodule volume was 19 ml; 1 year after MITT, volume reduction rate >50% and symptom relief were achieved in 89% and 93% of patients, respectively. No major complications occurred. Adding up pre-operative, operative and post-operative costs, total direct costs per single procedure are the following: 1361.43 € for LTA when using one optic fiber; 1761.43 € for LTA when using two optic fibers; 1968.53 € for RFA; 3338.39 € for hemithyroidectomy plus isthmectomy; 4034.99 € for total thyroidectomy. Surgery was impactful on direct-i.e., preoperative, operative and postoperative-costs, due to longer operating room occupation time and hospital stay. Overall, a total saving for the Italian National Health Service of 285,377.15 € has been obtained treating the 148 patients by MITT instead of surgery. Likewise, MITT was advantageous also for indirect costs-i.e., those related to "loss of productivity" caused by time off work due to hospital stay and recovery time-, for both the self-employed workers and the Government, the latter saving 53,838.50 € overall. Finally, intangible costs, related to patients' quality of life-e.g., residual surgical scar, stress related to general anesthesia, convalescence, and life-long intake of L-Thyroxine replacement therapy-were all in favor of MITT. This real-life cost-minimization analysis demonstrates that LTA and RFA are safe and cost-effective procedures for the treatment of SBTNs. In our 3 years experience, adding the savings of 285,377.15 € for direct costs to those of 53.838,50 € for indirect costs, in total 339,215.65 € were saved. The saving concern patients, the National Health System and the Government.
Sections du résumé
BACKGROUND
Prevalence of thyroid nodules is high in the adult population, approaching 60% in women and older people. Most thyroid nodules are benign and asymptomatic. However, a not negligible part of them causes compressive symptoms and/or cosmetic concerns and need to be treated. In the last two decades, minimally-invasive treatments of the thyroid (MITT) have been proposed in routine clinical practice as a reliable cost-effective alternative to surgery in patients with symptomatic benign thyroid nodules (SBTNs).
AIM OF THE STUDY
To perform a cost-minimization analysis comparing direct, indirect and intangible costs of radiofrequency (RFA) and laser thermal ablation (LTA) with traditional surgery in patients with SBTNs.
METHODS
Data of patients treated by MITT for SBTNs from October 1st 2019 to September 30th 2022 in a single Italian tertiary Center were analyzed. Costs were compared to those of traditional surgery reported in the 2022 Associazione Medici Endocrinologi Guidelines on the Management of SBTNs.
RESULTS
In the study lapse, 157 MITT of SBTNs were performed in 148 patients, 114 females and 34 males (mean age: 59 yrs; median age: 57 yrs). Before MITT, the mean thyroid nodule volume was 19 ml; 1 year after MITT, volume reduction rate >50% and symptom relief were achieved in 89% and 93% of patients, respectively. No major complications occurred. Adding up pre-operative, operative and post-operative costs, total direct costs per single procedure are the following: 1361.43 € for LTA when using one optic fiber; 1761.43 € for LTA when using two optic fibers; 1968.53 € for RFA; 3338.39 € for hemithyroidectomy plus isthmectomy; 4034.99 € for total thyroidectomy. Surgery was impactful on direct-i.e., preoperative, operative and postoperative-costs, due to longer operating room occupation time and hospital stay. Overall, a total saving for the Italian National Health Service of 285,377.15 € has been obtained treating the 148 patients by MITT instead of surgery. Likewise, MITT was advantageous also for indirect costs-i.e., those related to "loss of productivity" caused by time off work due to hospital stay and recovery time-, for both the self-employed workers and the Government, the latter saving 53,838.50 € overall. Finally, intangible costs, related to patients' quality of life-e.g., residual surgical scar, stress related to general anesthesia, convalescence, and life-long intake of L-Thyroxine replacement therapy-were all in favor of MITT.
CONCLUSIONS
This real-life cost-minimization analysis demonstrates that LTA and RFA are safe and cost-effective procedures for the treatment of SBTNs. In our 3 years experience, adding the savings of 285,377.15 € for direct costs to those of 53.838,50 € for indirect costs, in total 339,215.65 € were saved. The saving concern patients, the National Health System and the Government.
Identifiants
pubmed: 37258994
doi: 10.1007/s12020-023-03403-w
pii: 10.1007/s12020-023-03403-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
126-133Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
G. Grani, et al. Contemporary Thyroid Nodule Evaluation and Management. J. Clin. Endocrinol. Metab. 105(9), 2869–2883 (2020). https://doi.org/10.1210/clinem/dgaa322
doi: 10.1210/clinem/dgaa322
pubmed: 32491169
pmcid: 7365695
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016, 26 (2015)
C. Durante, G. Costante, G. Lucisano, et al. The natural history of benign thyroid nodules. J. Am. Med. Assoc. 313(9), 926–935 (2015). https://doi.org/10.1001/jama.2015.0956
doi: 10.1001/jama.2015.0956
T. Watt, L. Hegedüs, M. Groenvold, et al. Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur. J. Endocrinol. 162(1), 161–167 (2010). https://doi.org/10.1530/EJE-09-0521
doi: 10.1530/EJE-09-0521
pubmed: 19797502
D.K. Bartsch, et al. Current Practice of Surgery for Benign Goitre-An Analysis of the Prospective DGAV StuDoQ|Thyroid Registry. J. Clin. Med. 8(4), 477 (2019). https://doi.org/10.3390/jcm8040477 .
doi: 10.3390/jcm8040477
pubmed: 30965665
pmcid: 6517925
R. Novizio, The emergence of minimally-invasive procedures as a treatment for Thyroid Nodules. Vol. 7, Journal of Critical Reviews. July 2020 J. Crit. Rev. 7(17), 1783–1789 (2020). https://doi.org/10.31838/jcr.07.17.225
doi: 10.31838/jcr.07.17.225
LisaA. Orloff et al. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. Head. Neck 44(3), 633–660 (2022). https://doi.org/10.1002/hed.26960
doi: 10.1002/hed.26960
pubmed: 34939714
E. Papini, H. Monpeyssen, A. Frasoldati, L. Hegedüs, 2020 European Thyroid Association Clinical Practice Guideline for the Use of Image-Guided Ablation in Benign Thyroid Nodules. Eur. Thyroid J. 9(4), 172–185 (2020). https://doi.org/10.1159/000508484
doi: 10.1159/000508484
pubmed: 32903999
pmcid: 7445670
J.H. Kim, J.H. Baek, H.K. Lim, et al. 2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology. Korean J. Radio. 19(4), 632–655 (2018). https://doi.org/10.3348/kjr.2018.19.4.632
doi: 10.3348/kjr.2018.19.4.632
E. Papini, C.M. Pacella, L.A. Solbiati, et al. Minimally-invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group. Int. J. Hyperther. 36(1), 376–382 (2019). https://doi.org/10.1080/02656736.2019.1575482
doi: 10.1080/02656736.2019.1575482
L. Rudmik, M. Drummond, “Health economic evaluation: important principles and methodology.”. Laryngoscope 123(6), 1341–1347 (2013). https://doi.org/10.1002/lary.23943
doi: 10.1002/lary.23943
pubmed: 23483522
C.C. Lubitz, et al. Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer 120(9), 1345–1352 (2014). https://doi.org/10.1002/cncr.28562
doi: 10.1002/cncr.28562
pubmed: 24481684
H. Oda, et al. Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid. Endocr. J. 64(1), 59–64 (2017). https://doi.org/10.1507/endocrj.EJ16-0381
doi: 10.1507/endocrj.EJ16-0381
pubmed: 27667647
G. Russ, S.J. Bonnema, M.F. Erdogan et al. European Thyroid Association Guidelines for ultrasound malignancy risk stratification of thyroid nodules in adults: The EU-TIRADS. Eur. Thyroid J. 6, 225–237 (2017)
doi: 10.1159/000478927
pubmed: 29167761
pmcid: 5652895
F. Nardi, F. Basolo, A. Crescenzi, et al. Italian consensus for the classification and reporting of thyroid cytology. J. Endocrinol. Investig. (2014), https://doi.org/10.1007/s40618-014-0062-0 .
Associazione Medici Endocrinologi (AME). Linea Guida sulla gestione del nodulo benigno della tiroide causa di sintomi locali. Published in: Italian Sistema Nazionale Linee Guida (SNLG) of Istituto Superiore di Sanità (ISS), https://www.iss.it/ricerca?p_p_id=ricercawebcontentnew_INSTANCE_go5yaDEt7yac&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_ricercawebcontentnew_INSTANCE_go5yaDEt7yac_javax.portlet.action=go .
Job Pricing: All About Rewards – Salary Outlook 2019. Published in: www.jobpricing.it .
Istituto Italiano di Statistica, http://dati.istat.it .
M. Mathonnet, A. Cuerq, C. Tresallet, J.C. Thalabard, E. Fery-Lemonnier, G. Russ, L. Leenhardt, C. Bigorgne, P. Tuppin, B. Millat, A. Fagot-Campagna, What is the care pathway of patients who undergo thyroid surgery in France and its potential pitfalls?A National cohort. BMJ Open. 7(4), e013589 (2017). https://doi.org/10.1136/bmjopen-2016-013589 .
doi: 10.1136/bmjopen-2016-013589
pubmed: 28389487
pmcid: 5558818
Agenzia per la Rappresentanza Negoziale delle Pubbliche Amministrazioni (ARAN). Dati statistici. Published in: https://www.aranagenzia.it/statistiche-e-pubblicazioni/dat-statistici.hhtml .
C. Rossitto, S. Gueli Alletti, F. Romano, et al. Use of robot-specific resources and operating room times: the case of Telelap Alf-X robotic hysterectomy. J. Med. Rob. 12, 613–619 (2016)
M. Rai, R. Goyal, Pharmacoeconomics in healthcare. Pharm. Med. Transl. Clin. Res. chapter 33, 465–472 (2018). pages
doi: 10.1016/B978-0-12-802103-3.00034-1
R. Valcavi, R. Novizio, Side effects rates comparison in thyroid radiofrequency ablation between ambulatory setting and operating room setting. Thyroid ume 31(Supplement 1), 31–A127 (2021)
J.S. Sim, J.H. Baek, J. Lee, et al. Radiofrequency ablation of benign thyroid nodules: depicting early sign of regrowth by calculating vital volume. Int. J. Hyperth. 33, 905–910 (2017)
S. Spiezia, R. Garberoglio, F. Milone, et al. Thyroid nodules and related symptoms are stably controlled two year after radiofrequency thermal ablation. Thyroid 19, 219–225 (2009)
doi: 10.1089/thy.2008.0202
pubmed: 19265492
M. Mathonnet, A. Cuerq, C. Tresallet, J.C. Thalabard, E. Fery-Lemonnier, G. Russ, L. Leenhardt, C. Bigorgne, P. Tuppin, B. Millat, A. Fagot-Campagna, What is the care pathway of patients who undergo thyroid surgery in France and its potential pitfalls? A national cohort. BMJ Open 7(4), e013589 (2017). https://doi.org/10.1136/bmjopen-2016-013589 .
doi: 10.1136/bmjopen-2016-013589
pubmed: 28389487
pmcid: 5558818